Revolutionary Research Study on COPD Flare-Ups Now Available to Rock Hill Residents
A new research study focusing on Chronic Obstructive Pulmonary Disease (COPD) has been made accessible to the inhabitants of Rock Hill, S.C. Unveiled on December 11, 2023, the groundbreaking study seeks to deeply understand how an investigational treatment could potentially help reduce flare-ups of COPD symptoms in both current and former smokers.
Addressing the Seriousness of COPD
COPD is currently the sixth leading cause of mortality in the United States, implying a serious and grave public health crisis. This life-threatening pulmonary disease progressively gets worse over time, causing severe breathing problems. People inflicted with COPD tend to experience symptom flare-ups or exacerbations, which can persist for several days and may require hospitalization, progressively increasing the mortality rate.
Despite the availability of treatments for COPD, there persists an urgent need for safer and more effective options. To address this growing concern, the AERIFY-2 study initiated by Sanofi has been commenced to evaluate the efficacy of an experimental treatment, itepekimab, in reducing the severity of COPD symptom flare-ups.
Relief in Sight
According to Dr. Arun Adlakha, the principal investigator of this study in Rock Hill, around one in fourteen adults in South Carolina is afflicted with COPD, a count significantly higher than the national average. He expressed optimism about the study being offered locally and its potential impact on the community, making it considerably convenient for interested participants to join.
Care Access: Accelerating Medicinal Progress
In alignment with their mission to accelerate the arrival of cutting-edge medicines, Care Access, a global research company, plays an integral role in the study. With an impressive network of over 150 research sites worldwide, Care Access is committed to make clinical research more accessible while expanding it locally to increase representation.
The research study is also an outcome of Care Access’s collaborative efforts with local community leaders and healthcare providers. With its operations in Rock Hill, Care Access provides an option for residents to participate in clinical studies right in their own community.
This study currently enrolls current and former smokers aged between 40 to 85 who have been diagnosed with moderate to severe COPD. For more information about the study or to get involved, interested individuals can visit joincopdstudy.com or connect with Care Access at (351) 222-5112.
Conclusion
This novel research study is a significant step forward in the fight against COPD. By probing into new treatment possibilities and focusing on the reduction of COPD exacerbations, the study holds great promise to the millions suffering from this devastating disease. Moreover, being locally accessible, it encourages greater participation from the affected community and fosters hope for the development of safe and effective treatment options in the near future. Through a combined collaborative effort and cutting-edge research, there is background optimism about punching a blow against COPD.
